VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | SAL-DaunoDouble trial: 90 mg vs 60 mg daunorubicin in 7+3 induction for AML

Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, outlines the results from the SAL-DaunoDouble trial comparing 90 mg versus 60 mg in a standard 7+3 induction regimen for newly diagnosed acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter